October 2022—Cofactor Genomics presented initial results from the PREDAPT (Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies) multicenter clinical trial at the Advances in Genome Biology and Technology Precision Health Meeting in September. The company says its data show that Cofactor’s OncoPrism test using predictive immune modeling was nearly twice as accurate as PD-L1 assays in determining who will benefit from immunotherapies such as Keytruda (pembrolizumab).
The PREDAPT trial is studying whether a more comprehensive and quantitative profiling of the tumor microenvironment using the OncoPrism assay will lead to a more accurate prediction of responders to immune checkpoint inhibitors for a variety of cancers. The study currently includes 20 health care systems from across the nation, Cofactor says, and will ultimately study 11 solid tumor cancers.
In clinical studies where OncoPrism was tuned to have the same sensitivity as PD-L1, Cofactor’s test reached 75 percent accuracy in predicting responders to immune checkpoint inhibitors compared with 42 pecent accuracy for PD-L1, according to a Cofactor news release. The company says these interim results from nine health care systems show that at similar sensitivity, OncoPrism has greater specificity and continues to be superior to single-analyte approaches like PD-L1.
Cofactor Genomics, 888-602-0448